Hope fades … a mistake that turns Oxford’s calculations on its head

Oxford Vaccine

Get real time updates directly on you device, subscribe now.

The University of Oxford announced in a statement that some of the vials used in the experiment did not have the correct, concentrated amount of vaccine, so some volunteers got half the dose.

Although the world was pleased with many vaccines launched in the recent period, hoping to end the emerging coronavirus crisis that has been going on for almost a year, things are never well, so today, there is no conclusive evidence of the efficacy of this product, or failure Jealous.

In the midst of these experiments, the British company AstraZeneca, which developed the Corona vaccine jointly with the University of Oxford, admitted a manufacturing error, which raises questions about the experimental vaccine’s initial results.

This announcement came a few days after the company confirmed that the vaccine produced is highly effective.

In details, the company explained that the group of volunteers who got a lower dose of the vaccine appeared to be protected much better than the volunteers who got two full doses. Confirming that in the group with low doses, the vaccine appeared to be 90% effective. In the group that received two full doses, the vaccine appeared to be effective by 62% combined, so the final results are that the vaccine is 70% effective.

However, the companies accessed and reported how the results led to specific questions from the experts.

Partial results announced last Monday are from large studies underway in the United Kingdom and Brazil, with the mission of determining the optimal dose of the vaccine and examining safety and efficacy.

I tried multiple groups and doses in the volunteers than others, given the meningitis vaccine or a saline injection.

Did the researchers intend to give half a dose?

Before they begin their research, the scientists explain all the steps they will take and analyze the results, stressing that any deviation from this protocol can put the results into question.

However, Oxford University announced in a statement Wednesday that some of the vials used in the experiment did not have the correct, concentrated amount of vaccine, so some volunteers got half a dose.

The university said it discussed the organizers’ issue and agreed to complete the trial’s final phase with two groups.

The statement also stated that the manufacturing problem had been corrected.

What about the results themselves?

Experts report that the small number of people participating in the low dose group makes it difficult to know whether the group efficacy observed is real.

AstraZeneca said that about 2,741 people received half a dose of the vaccine, followed by a full dose, while a total of 8,895 people received two full doses.

And another factor, none of the people in the low dose group was older than 55, so it’s an incomplete experience because younger people usually tend to have a stronger immune response than the elderly, so younger people in the lower dose group may be: The reason it appears to be the most effective is not the size of the dose.

David Salisbury, a participant in the Global Health Program at the Chatham House Research Center, revealed that another point of confusion came from the decision to pool results from two groups of participants who received different dose levels to reach an average of 70% efficacy. He said: “I conducted two studies with different doses, and finally reached a compound that does not represent any of the doses…I think many people face a problem with that.”

Why is a smaller first dose more effective?

The Oxford researchers say they are not sure and are working to uncover the cause.
Sarah Gilbert, one of the Oxford scientists who led the research, explained that the answer might be related to providing the right amount of vaccine to stimulate the best immune response. She said: “The size of the dose is not a little or not a lot, as a lot may give you a bad response, so you only want the right amount; you will not get perfect the first time.”

What are the next steps?

Details of the trial results will be published in medical journals and presented to the UK regulators to determine whether or not to allow the vaccine to be distributed. These reports will include a detailed explanation that includes demographic information and other information about who has contracted the disease in each group—a complete picture of the vaccine’s effectiveness.

It is noteworthy that the British

Laboratory, AstraZeneca, had announced, last Monday, in a statement, that the vaccine against Covid-19, which it is developing jointly with the University of Oxford, is 70% effective in preventing disease.

The lab said they are tentative results of clinical trials conducted widely in the United Kingdom and Brazil.

However, he pointed out that this vaccine is less convincing than the Pfizer / Bionic and Moderna vaccines, whose effectiveness exceeds 90%, as it uses more traditional technology than the competing vaccines, which makes it less expensive and easier to store, as it does not need to be preserved at a low temperature.

In the statement, the company considered that its vaccine is “highly effective” to prevent disease, especially since no participants in the trials had any severe types of disease and no one was taken to hospital.

While the British authorities stressed that the data should be shared with the Medicines and Healthcare Products Regulatory Agency because it needs to ensure that it is effective and safe, of course.

Source: Websites